Investigators in Australia concluded that choroid plexus enlargement is associated with the expansion of chronic lesions and neurodegeneration ... in patients with relapsing-remitting ...

Roche Holdings AG's RHHBY Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS) met its primary and secondary endpoints. The data showed oral fenebrutinib ...

Relapsing-remitting MS People with all forms of MS can have lesions, but people with a common type of MS called relapsing-remitting MS generally have recurrent episodes of inflammatory demyelination.

Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults.

Furthermore, patients treated with fenebrutinib were four times more likely to be free from any new T1 Gd+ brain lesions and new or enlarging T2 brain lesions at weeks 4, 8 and 12 combined ...

Relapsing-remitting types of MS can have a pattern in which the lesions heal and then become inflamed and demyelinating again. With progressive types of MS, the lesions do not heal, and they can ...

"By week 120, performance on the timed 25-foot walk worsened by 38.9% with ocrelizumab versus 55.1% with placebo (P=0.04); the total volume of brain lesions on T2-weighted magnetic resonance ...

Cerebellum damage is common in relapsing-remitting MS and progressive forms of MS. In fact, it occurs in about 4 out of 5 people with the disease. But there’s no way to predict how MS will ...

Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS ...

– New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation ...

Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis F. Hoffmann-La Roche Ltd Wed, May 17, 2023, 1:00 AM 8 min read ...